Dr. Yang Wang is the Chief Technology Officer of ArriVent Biopharma. Dr. Wang has more than 17 years of experience in biopharmaceutical process development and commercialization. Most recently, she served as SVP, Head of CMC at Viela Bio, where she oversaw all aspects of process development, manufacturing, and supply of clinical and commercial products across the portfolio. Previously, Dr. Wang was Senior Director, Analytical Sciences at Biopharmaceutical Development, MedImmune, where she made key contributions to the BLA/MAA approval of three novel biologics. Dr. Wang also served as Director, Purification Process Sciences at MedImmune, and was responsible for leading the development of scalable downstream process for multiple complex novel molecules. Earlier in her career, she served as Chemistry Manufacturing and Controls Team Leader. Prior to joining MedImmune in 2009, Dr. Wang worked at Amgen and Pfizer in roles of increasing responsibility in process development, characterization, technology transfer, commercial manufacturing support and post-approval changes. She completed her Ph.D. in Biochemistry from University of Virginia, followed by Postdoctoral Research at Department of Cellular and Molecular Pharmacology at University of California, San Francisco.